Advaxis, Inc. Partners With Gynecologic Oncology Group For Phase II Study of Company's Lead Cervical Cancer Vaccine

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS) has received confirmation that the Gynecologic Oncology Group (GOG), a therapeutic clinical research group of the National Cancer Institute (NCI) has agreed to conduct and help fund a future Phase II trial of Lovaxin C. This trial is expected to begin following completion of the Company’s current Phase I/II trial. To date, Advaxis has completed enrollment and dosing of the first two of four cohorts consisting of patients diagnosed with advanced, recurrent or progressive cervical cancer. Review by an independent safety panel has found that this assessment, the first in humans, of a modified Listeria-based live vaccine is safe. Dosage escalation is ongoing.